Vesalio Announces Oversubscribed Class A Financing

Nashville, TN May 18, 2022 --(PR.com)-- Vesalio, an emerging leader in improving outcomes in patients
with vascular occlusion, is proud to announce it has oversubscribed its Class A financing round. Solas
BioVentures led the investment with participation by new and existing investors, including the recent
addition of Orlando Health Ventures.

With an expanding customer base established in Europe, Vesalio will use this funding to enter the U.S.
market by executing FDA clearances, adding key personnel, developing support infrastructure, expanding
its product portfolio, and completing its cardiology clinical study.

“This financing round advances Vesalio’s mission to improve outcomes in patients suffering a stroke and
other conditions created by blood clots,” said Mike Kujak, Vesalio Board Chairman. “As the medical
field continues to evolve in treating vascular occlusion, physicians are seeking a device that effectively
removes all types of blood clots to improve patient outcomes by reducing the time it takes to restore
blood flow. This oversubscribed round of funding allows us to complete the development and
introduction of new technology and accelerate the market growth of Vesalio’s proprietary platforms.”

Vesalio is also pleased to announce a new addition to its board of directors: Bobby Helmedag, the
managing director of Orlando Health Ventures. “We are excited to be Vesalio investors,” expressed Mr.
Helmedag. “Their NeVa and enVast platforms have shown extremely promising results, and we look
forward to supporting them as they scale global markets and enter the U.S. market. And importantly,
CEO Steve Rybka has assembled a top-notch team prepared to drive market penetration through
Vesalio’s next wave of growth.”

About Vesalio
Founded in 2013, Vesalio is a privately-held medical device company focused on advancing patient care
in vascular occlusion by providing physicians with superior technology designed to improve clinical
outcomes. Vesalio’s proprietary NeVa™ platform is designed to consistently achieve first-pass
recanalization in acute ischemic stroke by effectively removing all types of neurovascular clots from a
patient’s anatomy. For more information, visit vesalio.com.

About Solas BioVentures

Solas BioVentures is a venture capital firm that invests exclusively in the life science industry, focusing
on early and development stage Biotech and MedTech companies advancing impactful, disruptive
technologies. Headquartered in Chattanooga, Tennessee, its coverage is global. For more information,
visit solasbio.com.

About Orlando Health Ventures

Orlando Health Ventures is the venture arm of Orlando Health, a not-for-profit healthcare organization
with $8 billion of assets under management that serves the southeastern United States and is
headquartered in Orlando, Florida. Orlando Health is a 3,200-bed system that includes: 10 award-winning
hospitals, 9 hospital-based ERs, 7 freestanding emergency rooms, rehabilitation services, cancer and heart

Page 1 of 4
PR.com Press Release Distribution Terms
institutes, imaging and laboratory services, wound care centers, physician offices for adults and
pediatrics, skilled nursing facilities, an in-patient behavioral health facility, home healthcare services in
partnership with LHC Group, and urgent care centers in partnership with FastMed Urgent Care. More
than 4,200 physicians representing more than 100 medical specialties and subspecialties have privileges
across the Orlando Health system, which employs more than 23,000 team members.

Page 2 of 4
PR.com Press Release Distribution Terms
Contact Information:
Vesalio
William von Brendel
858-335-5790
Contact via Email
www.vesalio.com

Online Version of Press Release:

https://www.pr.com/press-release/861618

Page 3 of 4
PR.com Press Release Distribution Terms
 Page 4 of 4
PR.com Press Release Distribution Terms